Johnson & Johnson $JNJ Stock: HighTower Advisors LLC Reduces Position

HighTower Advisors LLC cut its position in Johnson & Johnson (NYSE:JNJ – Free Report) by 0.4% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 9,849,187 shares of the company’s stock after selling 43,580 shares during the period. Johnson & Johnson makes up 2.5% of HighTower Advisors LLC’s holdings, making the stock its 4th largest position. HighTower Advisors LLC owned approximately 0.41% of Johnson & Johnson worth $2,607,474,000 at the end of the most recent quarter.

Several other institutional investors have also recently modified their holdings of JNJ. Outlook Capital Management LLC purchased a new stake in Johnson & Johnson in the second quarter valued at approximately $28,000. Matrix Trust Co raised its position in Johnson & Johnson by 56.2% during the 2nd quarter. Matrix Trust Co now owns 150 shares of the company’s stock worth $38,000 after buying an additional 54 shares during the last quarter. Navigoe LLC lifted its stake in Johnson & Johnson by 60.4% during the 3rd quarter. Navigoe LLC now owns 146 shares of the company’s stock valued at $38,000 after acquiring an additional 55 shares during the period. Montgomery Financial Services LLC acquired a new stake in Johnson & Johnson during the 2nd quarter valued at approximately $43,000. Finally, Hanseatic Management Services Inc. purchased a new stake in shares of Johnson & Johnson in the 3rd quarter valued at $52,000. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

JNJ has been the topic of a number of research reports. Guggenheim reiterated a “buy” rating and issued a $287.00 price objective on shares of Johnson & Johnson in a research note on Wednesday, October 7th. TD Cowen restated a “buy” rating on shares of Johnson & Johnson in a research report on Tuesday, October 20th. Evercore set a $300.00 price target on shares of Johnson & Johnson in a report on Tuesday, October 20th. Royal Bank Of Canada cut their price target on Johnson & Johnson from $290.00 to $280.00 and set an “outperform” rating on the stock in a research report on Wednesday, October 14th. Finally, Sanford C. Bernstein set a $270.00 price objective on Johnson & Johnson in a research note on Thursday, October 15th. One investment analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and eight have issued a Hold rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $275.92.

View Our Latest Stock Analysis on Johnson & Johnson

Insiders Place Their Bets

In other Johnson & Johnson news, EVP Timothy Schmid sold 33,597 shares of Johnson & Johnson stock in a transaction on Wednesday, September 2nd. The shares were sold at an average price of $274.74, for a total value of $9,230,439.78. Following the completion of the transaction, the executive vice president owned 25,447 shares of the company’s stock, valued at approximately $6,991,308.78. The trade was a 56.90% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Elizabeth Forminard sold 13,072 shares of the company’s stock in a transaction dated Thursday, November 12th. The stock was sold at an average price of $284.39, for a total transaction of $3,717,546.08. Following the completion of the transaction, the executive vice president owned 16,994 shares of the company’s stock, valued at approximately $4,832,923.66. This trade represents a 43.48% decrease in their position. The disclosure for this sale is available in the SEC filing. 0.16% of the stock is currently owned by insiders.

Johnson & Johnson Trading Down 1.1%

Johnson & Johnson stock opened at $282.62 on Tuesday. The firm has a market cap of $680.36 billion, a PE ratio of 42.82, a P/E/G ratio of 2.80 and a beta of 0.22. Johnson & Johnson has a 12 month low of $195.90 and a 12 month high of $290.25. The stock’s 50 day simple moving average is $267.12 and its two-hundred day simple moving average is $250.12. The company has a current ratio of 1.02, a quick ratio of 0.74 and a debt-to-equity ratio of 0.44.

Johnson & Johnson (NYSE:JNJ – Get Free Report) last posted its earnings results on Tuesday, October 13th. The company reported $2.59 earnings per share for the quarter, beating the consensus estimate of $2.53 by $0.06. Johnson & Johnson had a net margin of 16.20% and a return on equity of 31.64%. The firm had revenue of $25.40 billion during the quarter, compared to analyst estimates of $25.38 billion. During the same period in the previous year, the firm earned $2.80 EPS. The business’s quarterly revenue was up 5.9% on a year-over-year basis. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. Analysts anticipate that Johnson & Johnson will post 11.12 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 8th. Investors of record on Tuesday, November 24th will be given a dividend of $1.34 per share. This represents a $5.36 annualized dividend and a yield of 1.9%. The ex-dividend date is Tuesday, November 24th. Johnson & Johnson’s dividend payout ratio (DPR) is currently 81.21%.

Key Johnson & Johnson News

These are some of the JNJ news items that stood out recently:

  • Positive Sentiment: J&J will pay $2.2 billion upfront for Ollin, with up to about $1.1 billion in additional regulatory and commercial milestone payments. The acquisition adds OLN324, a late-stage antibody being developed for wet age-related macular degeneration and diabetic macular edema, and could complement J&J’s existing eye-care business. J&J bets $2.2B on Ollin’s vision loss drug
  • Positive Sentiment: Blackstone Life Sciences will provide $750 million to fund OLN324’s Phase 3 program, helping support development of the drug while sharing its funding burden. Blackstone Life Sciences Announces $750 Million R&D Funding Agreement
  • Neutral Sentiment: OLN324 is still investigational, so its commercial prospects depend on successful trials, regulatory approval and uptake. The retinal-disease market is crowded and competitive, which could limit eventual returns on the acquisition. J&J outlays up to $3.3bn to buy ophthalmology specialist Ollin Biosciences

Johnson & Johnson Company Profile

(Free Report)

Johnson & Johnson is a global healthcare company that develops and sells prescription medicines and medical technologies. Its business is organized around two segments: Innovative Medicine and MedTech. Innovative Medicine develops treatments in areas including oncology, immunology, neuroscience, cardiovascular and metabolic disease, and pulmonary hypertension. MedTech provides products and technologies for fields such as surgery, orthopedics, and vision care. Founded in 1886, Johnson & Johnson serves patients and healthcare professionals in markets around the world.

Further Reading

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Free Report).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.